These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 17682150)

  • 1. [Gene therapy for breast cancer].
    Takahashi S; Sugimoto Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():135-41. PubMed ID: 17682150
    [No Abstract]   [Full Text] [Related]  

  • 2. [Gene therapy for relapsed breast cancer].
    Takahashi S; Sugimoto Y
    Nihon Rinsho; 2006 Mar; 64(3):563-9. PubMed ID: 16529050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gene therapy for breast cancer].
    Miki Y
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():522-5. PubMed ID: 16416846
    [No Abstract]   [Full Text] [Related]  

  • 4. [Genetic alterations and expression changes in breast cancers].
    Terada K; Ushijima T
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():113-9. PubMed ID: 17682148
    [No Abstract]   [Full Text] [Related]  

  • 5. [Gene therapy for breast cancer].
    Takeda Y; Eriguchi M
    Nihon Rinsho; 2001 Jan; 59(1):110-8. PubMed ID: 11197840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
    Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
    Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients.
    Austrup F; Uciechowski P; Eder C; Böckmann B; Suchy B; Driesel G; Jäckel S; Kusiak I; Grill HJ; Giesing M
    Br J Cancer; 2000 Dec; 83(12):1664-73. PubMed ID: 11104564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of retroviral and adenoviral approaches to cancer gene therapy.
    Yin LH; Fu SQ; Nanakorn T; Garcia-Sanchez F; Chung I; Cote R; Pizzorno G; Hanania E; Heimfeld S; Crystal R; Deisseroth A
    Stem Cells; 1998; 16 Suppl 1():247-50. PubMed ID: 11012168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
    Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
    Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer.
    Bièche I; Lidereau R
    Mol Carcinog; 2000 Nov; 29(3):151-8. PubMed ID: 11108660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
    Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K
    Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members.
    Chada S; Mhashilkar AM; Liu Y; Nishikawa T; Bocangel D; Zheng M; Vorburger SA; Pataer A; Swisher SG; Ramesh R; Kawase K; Meyn RE; Hunt KK
    Cancer Gene Ther; 2006 May; 13(5):490-502. PubMed ID: 16282987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model.
    Hanania EG; Deisseroth AB
    Clin Cancer Res; 1997 Feb; 3(2):281-6. PubMed ID: 9815684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
    Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
    Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
    Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
    Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer.
    Têtu B; Brisson J; Plante V; Bernard P
    Mod Pathol; 1998 Sep; 11(9):823-30. PubMed ID: 9758361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance.
    Koç ON; Allay JA; Lee K; Davis BM; Reese JS; Gerson SL
    Semin Oncol; 1996 Feb; 23(1):46-65. PubMed ID: 8607032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
    Wright M; Grim J; Deshane J; Kim M; Strong TV; Siegal GP; Curiel DT
    Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
    Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
    Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.